Oops, something went wrong
By Bhanvi Satija, Oliver Hirt and Marleen Kaesebier
LONDON/ZURICH, Sept 11 (Reuters) - Novartis investors are set to step up scrutiny of the Swiss group's dealmaking strategy after setbacks to drugs it acquired through mergers and acquisitions hit its shares, raising concerns about its pipeline.
Eight shareholders told Reuters that muscle-wasting disorder drug del-desiran's failure in a late-stage study, the second major trial setback for Novartis in days, raised questions over last year's $12 billion Avidity purchase and other acquisitions.
Novartis shares slumped 11% in one day this week, wiping nearly $30 billion off its market value and all the gains made since the start of the year after the del-desiran results.
